J
Jenny Heathcote
Researcher at University of Toronto
Publications - 147
Citations - 15265
Jenny Heathcote is an academic researcher from University of Toronto. The author has contributed to research in topics: Hepatitis B & Hepatitis C. The author has an hindex of 49, co-authored 147 publications receiving 14829 citations. Previous affiliations of Jenny Heathcote include University Health Network & Royal Free Hospital.
Papers
More filters
Journal ArticleDOI
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
Fernando Alvarez,P.A. Berg,Francesco B. Bianchi,Leonardo Bianchi,A.K. Burroughs,Eduardo Luiz Rachid Cançado,Roger W. Chapman,W. G. E. Cooksley,Albert J. Czaja,V J Desmet,Peter T. Donaldson,A. L. W. F. Eddleston,L. Fainboim,Jenny Heathcote,Jean-Claude Homberg,Jay H. Hoofnagle,Shinichi Kakumu,Edward L. Krawitt,Ian R. Mackay,R. N. M. Macsween,Willis C. Maddrey,Michael P. Manns,I.G. McFarlane,K H Meyer zum Büschenfelde,G. Mieli-Vergani,Yasuni Nakanuma,Mikio Nishioka,Edward Penner,Gilda Porta,Bernard Portmann,W. D. Reed,Joan Rodés,Solko W. Schalm,P. J. Scheuer,Erik Schrumpf,Takeshi Seki,Gotaro Toda,Takao Tsuji,Niels Tygstrup,Diego Vergani,Mikio Zeniya +40 more
Journal ArticleDOI
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.
Journal ArticleDOI
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.
TL;DR: A meta-analysis of randomized, controlled trials was conducted to examine the efficacy of interferon treatment in patients with chronic HBV infection as determined by the loss of HBsAg, HBeAg, and HBV DNA.
Journal ArticleDOI
EASL International Consensus Conference on Hepatitis C, Paris, 26-28 February 1999: Consensus Statement
Jean-Pierre Benhamou,Joan Rodés,H. Alter,H. Bismuth,Valeer Desmet,Jaime Guardia,Jenny Heathcote,Anna S.F. Lok,Willis C. Maddrey,K. H M Zum Buschenfelde,L. Pagliaro,Gustav Paumgartner,Sheila Sherlock +12 more
Journal ArticleDOI
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial
Solko W. Schalm,Jenny Heathcote,J. Cianciara,G. Farrell,Mark E. Sherman,Bernard Willems,Amar P. Dhillon,AE Moorat,Judy Barber,DF Gray +9 more
TL;DR: The combination of lamivudine and interferon appeared to increase the HBeAg seroconversion rate, particularly in patients with moderately elevated baseline aminotransferase levels, and the potential benefit of combining lamivUDine andInterferon should be investigated further in studies with different regimens of combination therapy.